The Ride For Roswell, the single largest fundraising event in Western New York and North America’s largest single-day cycling fundraiser, concluded its 21st year this weekend by raising a total of $4.5 million for cancer research and patient-care programs at Roswell Park Cancer Institute (RPCI).

Knowing how much exercise is enough to prevent health problems can be confusing, but two recent studies led by Roswell Park Comprehensive Cancer Center have shown that years of physical inactivity prior to diagnosis was associated with increased risk of developing ovarian cancer and of dying from the disease.

Kazuaki Takabe, MD, PhD, FACS, Clinical Chief of Breast Surgery, Alfiero Foundation Chair and Breast Program Leader at Roswell Park Cancer Institute, is in Washington, D.C., today as a leader of the 4th U.S.–Japan Clinical Trials in Oncology Workshop.

Roswell Park Cancer Institute today announced at the BIO International Convention the formation of Global Biotechnology & Cancer Therapeutics, a company that will guide and support biotech and life-sciences startups. The partnership links Roswell Park’s world-class cancer research capabilities with GBCT’s expertise in assisting biotechnology and cancer therapeutics startup companies, including those arising from Roswell Park’s own laboratories.

The ability of tumor-infiltrating lymphocytes (TILs) such as T cells to produce multitudes of clones that overwhelm and effectively control cancer cells has been demonstrated, but the significance of the composition of T-cell repertories is unknown. Roswell Park Cancer Institute (RPCI) researchers used deep T-cell receptor (TCR) sequencing to evaluate the clonal composition of TILs and identify novel prognostic biomarkers in ovarian cancer. The findings will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results of the phase III clinical study conducted by physician-scientists at multiple centers, including Roswell Park Cancer Institute (RPCI), will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents. The results of a study led by researchers at Roswell Park Cancer Institute (RPCI) and Columbia University Medical Center used advanced imaging methods to evaluate obesity and suggest a relationship between obesity and disease relapse. The team’s findings will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.